The Positive
+ Healthcare Services continued its strong performance. The 8.0% YoY increase in revenue from Healthcare Services division was due to insurance income, the addition of new corporate clients and a new Air Borders Screening contract with MOH (Ministry of Health) have lent support in the uplift.
+Cost management fairly executed. Staff cost managed to contract5% YoY and 3.5% QoQ despite the expansion in facilities. 3Q18 staff costs make up 51.5% of revenue, and we expect it to remain above 50% of the Group’s revenue in the coming quarters until patient volume picks up in RafflesHospital Extension, MCH and the two new hospitals in China.
The Negative
– Continued pressure from public hospitals and medical tourism. The 3.8% YoY decline in Hospital revenues was due to the refurbishment of the current inpatient facilities, decelerating foreign patient load and public hospitals. Public hospitals account for 80% of the total beds, and they have the critical mass of subsidised patients to offer a more competitive price, if necessary. The growth of foreign patients continues to decelerate as the stronger Singapore dollar relative to regional countries make options in Bangkok, Kuala Lumpur and Penang more attractive. The more price sensitive customer base will look for a cheaper alternative as Singapore’s cost of living in becomes more expensive. We trim our FY18-19e revenue estimates by 3-9% to account for slower Singapore revenue growth.
Outlook
China
Expect some front-loading of staff cost as Chongqing hospital opens in 4Q18. There will be the typical start-up costs (staff and depreciation) before beds start to fill up. Management is expecting EBITDA loss of S$8-10mn and S$4-5mn in the first and second year respectively as the Chongqing hospital breaks even in the third year of operation. In its initial phase, approximately 100 staff (doctors, nurses and administrators) will be employed to cater to the major disciplines. The Shanghai hospital is expected to open in 2H19.
Health Insurance
The recent strategic partnerships in the health insurance industry provide an opportunity to increase patient volume by offering policyholders access to a panel of specialists at Raffles Hospital. Estimated potential IP revenue is S$10m-12m, targeting 25,000 new policyholders in its first year. We are optimistic about Raffles Medical’s move into the health insurance scene in Singapore as well as in China when the Chongqing and Shanghai hospitals open in 4Q18 and 2H19 respectively.
Singapore
In collaboration with MOH, RafflesHospital opened a new inpatient ward this quarter catering to the needs of patients under the Emergency Care. Renovation works are expected in the next quarter to add more inpatient facilities to support the Group’s growth strategies in 2019.
Maintain Accumulate with lower TP of S$1.16 (previous TP S$1.32)
The insatiable demand for international standard healthcare by the Chinese middle class will bring Raffles Medical into a new and exciting phase of growth. The track record, reputation and preparation by the company makes this a compelling opportunity.
Potential re-rating catalysts: (i) Stronger demand from the MOH partnership; and (ii) Better than expected performance in China hospitals.
Important Information
This report is prepared and/or distributed by Phillip Securities Research Pte Ltd ("Phillip Securities Research"), which is a holder of a financial adviser’s licence under the Financial Advisers Act, Chapter 110 in Singapore.
By receiving or reading this report, you agree to be bound by the terms and limitations set out below. Any failure to comply with these terms and limitations may constitute a violation of law. This report has been provided to you for personal use only and shall not be reproduced, distributed or published by you in whole or in part, for any purpose. If you have received this report by mistake, please delete or destroy it, and notify the sender immediately.
The information and any analysis, forecasts, projections, expectations and opinions (collectively, the “Research”) contained in this report has been obtained from public sources which Phillip Securities Research believes to be reliable. However, Phillip Securities Research does not make any representation or warranty, express or implied that such information or Research is accurate, complete or appropriate or should be relied upon as such. Any such information or Research contained in this report is subject to change, and Phillip Securities Research shall not have any responsibility to maintain or update the information or Research made available or to supply any corrections, updates or releases in connection therewith.
Any opinions, forecasts, assumptions, estimates, valuations and prices contained in this report are as of the date indicated and are subject to change at any time without prior notice. Past performance of any product referred to in this report is not indicative of future results.
This report does not constitute, and should not be used as a substitute for, tax, legal or investment advice. This report should not be relied upon exclusively or as authoritative, without further being subject to the recipient’s own independent verification and exercise of judgment. The fact that this report has been made available constitutes neither a recommendation to enter into a particular transaction, nor a representation that any product described in this report is suitable or appropriate for the recipient. Recipients should be aware that many of the products, which may be described in this report involve significant risks and may not be suitable for all investors, and that any decision to enter into transactions involving such products should not be made, unless all such risks are understood and an independent determination has been made that such transactions would be appropriate. Any discussion of the risks contained herein with respect to any product should not be considered to be a disclosure of all risks or a complete discussion of such risks.
Nothing in this report shall be construed to be an offer or solicitation for the purchase or sale of any product. Any decision to purchase any product mentioned in this report should take into account existing public information, including any registered prospectus in respect of such product.
Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the issuance of this report, may provide an array of financial services to a large number of corporations in Singapore and worldwide, including but not limited to commercial / investment banking activities (including sponsorship, financial advisory or underwriting activities), brokerage or securities trading activities. Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the issuance of this report, may have participated in or invested in transactions with the issuer(s) of the securities mentioned in this report, and may have performed services for or solicited business from such issuers. Additionally, Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the issuance of this report, may have provided advice or investment services to such companies and investments or related investments, as may be mentioned in this report.
Phillip Securities Research or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the issuance of this report may, from time to time maintain a long or short position in securities referred to herein, or in related futures or options, purchase or sell, make a market in, or engage in any other transaction involving such securities, and earn brokerage or other compensation in respect of the foregoing. Investments will be denominated in various currencies including US dollars and Euro and thus will be subject to any fluctuation in exchange rates between US dollars and Euro or foreign currencies and the currency of your own jurisdiction. Such fluctuations may have an adverse effect on the value, price or income return of the investment.
To the extent permitted by law, Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the issuance of this report, may at any time engage in any of the above activities as set out above or otherwise hold an interest, whether material or not, in respect of companies and investments or related investments, which may be mentioned in this report. Accordingly, information may be available to Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the issuance of this report, which is not reflected in this report, and Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the issuance of this report, may, to the extent permitted by law, have acted upon or used the information prior to or immediately following its publication. Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited its officers, directors, employees or persons involved in the issuance of this report, may have issued other material that is inconsistent with, or reach different conclusions from, the contents of this report.
The information, tools and material presented herein are not directed, intended for distribution to or use by, any person or entity in any jurisdiction or country where such distribution, publication, availability or use would be contrary to the applicable law or regulation or which would subject Phillip Securities Research to any registration or licensing or other requirement, or penalty for contravention of such requirements within such jurisdiction.
This report is intended for general circulation only and does not take into account the specific investment objectives, financial situation or particular needs of any particular person. The products mentioned in this report may not be suitable for all investors and a person receiving or reading this report should seek advice from a professional and financial adviser regarding the legal, business, financial, tax and other aspects including the suitability of such products, taking into account the specific investment objectives, financial situation or particular needs of that person, before making a commitment to invest in any of such products.
This report is not intended for distribution, publication to or use by any person in any jurisdiction outside of Singapore or any other jurisdiction as Phillip Securities Research may determine in its absolute discretion.
IMPORTANT DISCLOSURES FOR INCLUDED RESEARCH ANALYSES OR REPORTS OF FOREIGN RESEARCH HOUSE
Where the report contains research analyses or reports from a foreign research house, please note:
Min Ying covers the Banking and Finance sectors. She has experience in external audit and corporate tax roles.
She graduated with a Bachelor of Accountancy with a major in Finance from SMU.
